SALT LAKE CITY, July 2, 2026
Myriad Genetics, Inc. announced the publication of the largest individual-patient-data meta-analysis evaluating its Prolaris® Biopsy Test, demonstrating that the molecular diagnostic test provides significant prognostic information beyond conventional clinical risk assessments for patients with localized prostate cancer. Published in Clinical Genitourinary Cancer, the comprehensive analysis combined data from 14 clinical studies involving more than 8,000 patients, including 7,924 patients with individual participant data, confirming that Prolaris enhances risk stratification for disease progression, distant metastasis, and prostate cancer-specific mortality. The findings strengthen the clinical evidence supporting the use of Prolaris to guide personalized treatment planning and shared decision-making for men newly diagnosed with localized prostate cancer.
Largest Meta-Analysis Validates Prognostic Performance
The newly published study, titled “Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer,” evaluated the performance of the Prolaris Clinical Cell-Cycle Risk (CCR) Score across multiple patient populations and treatment strategies. Researchers found that the CCR score was strongly predictive of distant metastasis and prostate cancer-specific mortality across all National Comprehensive Cancer Network (NCCN) risk groups. Importantly, the analysis demonstrated that Prolaris provides independent prognostic value beyond established clinical tools, including the Gleason Score, CAPRA Score, and traditional NCCN risk classifications, enabling clinicians to better distinguish individual patient risk using molecular insights alongside standard clinical assessments.
Precision Diagnostics Support Personalized Treatment Decisions
The Prolaris Biopsy Test analyzes gene expression from prostate biopsy tissue and combines these molecular findings with clinical information to generate a personalized CCR score. This information helps physicians determine whether patients may be suitable for active surveillance, require definitive treatment, or benefit from more aggressive therapeutic strategies. Study author Dr. Steven Monda of the University of Michigan Health noted that the tissue-based RNA assay delivers valuable prognostic information even among low-risk prostate cancer patients, where treatment decisions can often be challenging. The ability to better predict prostate cancer-specific mortality supports more informed patient counseling while helping clinicians tailor surveillance intensity and treatment planning according to individual disease biology.
Advertisement
Evidence Strengthens Precision Medicine in Prostate Cancer
The large-scale analysis further reinforces Myriad Genetics’ position in precision oncology by demonstrating that Prolaris performs consistently across diverse patient populations, risk categories, and initial management approaches. The company emphasized that the robust evidence supports broader clinical adoption of molecular diagnostics to improve individualized prostate cancer care. In addition to its established clinical utility, Prolaris has recently expanded with AI-powered digital pathology features, further enhancing its role in precision medicine. As molecular testing continues to become an increasingly important component of cancer management, the latest findings provide strong evidence that Prolaris delivers clinically meaningful prognostic information that can improve treatment selection, optimize patient outcomes, and support personalized care for men with localized prostate cancer.
Source:Myriad Genetics press release
